Projektbeschreibung
Synthetische Embryonen dienen dem Studium der Embryonalentwicklung
Der Zeitraum der Embryonalentwicklung ist für das Überleben und die Fitness eines jeden Organismus von zentraler Bedeutung. Die begrenzte Verfügbarkeit menschlicher Embryonen stellt jedoch ein Hindernis bei der Erforschung der menschlichen Embryogenese dar, und viele Aspekte sind bisher noch ungeklärt. Das EU-finanzierte Projekt BLASTOID zielt darauf ab, synthetische Embryonen aus menschlichen Stammzellen zu entwickeln, die sich zu Präimplantationsblastozysten zusammenfügen. Zusammen mit Gebärmutter-Organoiden können diese Blastoide in der Forschung dazu genutzt werden, den Prozess der Embryogenese und der Einnistung zu untersuchen. Diese Stammzellen können gentechnisch verändert werden. Daher sind sie ein leistungsfähiges In-vitro-Instrument für die Untersuchung von Medikamenten zur Verbesserung des Einnistungsvorgangs.
Ziel
The first weeks of human embryonic development are crucial. Early abnormalities or insults result not only in infertility, but also contribute to long-term impairment of human health (e.g. cardiovascular disease and diabetes). Managing the onset of pregnancy therefore offers a huge opportunity to improve public health through effective family planning and disease prevention.
To better manage pregnancy, biomedical research would require large numbers of human embryos for use in genetic and drug screening. Unfortunately, however, the scarcity of human embryos makes this impossible. Recently, hope for an alternative approach has come from work in my lab showing that mouse stem cells self-organize into structures closely resembling pre-implantation embryos (a.k.a. blastocysts), that we termed blastoids. Because stem cells can be largely expanded and genetically-modified, these synthetic embryos provide a powerful, scalable alternative that is amenable to drug and genetic screens, thus opening numerous possibilities for therapeutic breakthroughs.
Here, I propose the development of human blastoids and uterine organoids to model embryogenesis and uterine implantation in vitro. This platform will be used to identify potential targets for the therapeutic modulation of the molecular pathways that control (1) early embryogenesis and (2) interactions between the embryo and uterus, and will pave the way to (3) establishing a drug discovery pipeline for the management of implantation.
This project will generate key insights into druggable molecules controlling early human embryogenesis, facilitating identification of therapeutic targets to improve in vitro fertilization (IVF) procedures and contraception and, ultimately, to prevent several chronic diseases.
Wissenschaftliches Gebiet
- medical and health sciencesbasic medicinepharmacology and pharmacydrug discovery
- natural sciencesbiological sciencesdevelopmental biology
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicineobstetrics
- medical and health sciencesclinical medicineembryology
Programm/Programme
Thema/Themen
Finanzierungsplan
ERC-COG - Consolidator GrantGastgebende Einrichtung
1030 Wien
Österreich